Recruiting PHASE2 INTERVENTIONAL 1-arm NCT05970666

Single Arm, Prospective, Multicenter Clinical Study of TACE With Adebrelimab and Bevacizumab for Unresectable Hepatocellular Carcinoma

Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Conditions Adebrelimab Bevacizumab Hepatocellular Carcinoma TACE Transformation

Interventions TACE with adebrelimab and bevacizumab

Updated 5 times since 2023 Last updated: Feb 27, 2024 Started: Nov 15, 2023 Primary completion: Nov 15, 2026 Completion: Nov 15, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Adebrelimab and Bevacizumab and is currently actively recruiting participants. Jiangsu HengRui Medicine Co., Ltd. leads this study, which shows 5 recorded versions since 2023 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE2
Mar 2024 — Jul 2024 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Nov 2023 — Mar 2024 [monthly]

Not Yet Recruiting PHASE2
Sep 2023 — Nov 2023 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Jiangsu HengRui Medicine Co., Ltd.
The First Affiliated Hospital of Xiamen University

Data source: The First Affiliated Hospital of Xiamen University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Xiamen, China